Departments of Urology, Radiology, and Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas.

Department of Urology, The First Hospital of Xi'an Jiaotong University, Xi'an, China.

Romidepsin (FK228, depsipeptide, FR901228), a unique cyclic depsipeptide with a histone deacetylase inhibitor (HDACI) activity, is a potential cancer therapeutic agent and currently under clinical trials for several types of cancer. For bladder cancer, romidepsin seems to be a potent antitumor agent from our recent study. In this study, we further delineate a new agent that can enhance both HDACI and antitumor activity of romidepsin.

We screened a chemical library to identify candidate(s) that could enhance romidepsin activity. Chemical synthesis and purification were carried out to produce pure compound to examine its biochemical and antitumor effect on bladder cancer cell lines both in vitro and in vivo.

Tranilast, N-(acetoacetyl) anthranilic acid, was first identified as a lead compound from screening, and then, one of the analogues, 2,3-dimethoxycinnamoyl azide (DMCA), seems to be more potent than tranilast. Our data indicate that DMCA can potentiate the HDACI activity of romidepsin and other biological activities, such as cell cycle arrest and apoptosis; these effects were accompanied with the expression of various key cell cycle regulators in different bladder cancer cells. Consistently, DMCA can enhance the in vivo antitumor effect of romidepsin without causing any more weight loss than romidepsin alone.

DMCA is able to enhance the antitumor effect of romidepsin on bladder cancer from in vitro and in vivo.

Written by
Fan J, Stanfield J, Guo Y, Karam JA, Frenkel E, Sun X, Hsieh JT.

Reference
Clin Cancer Res. 2008 Feb 15;14(4):1200-7.

PubMed Abstract
PMID:18281555

UroToday.com Bladder Cancer Section

Please log-in or register in order to submit comments.

Powered by AkoComment!